Mankind Pharma Q3 Results: Net profit falls 16% to Rs 384 crore

Mankind Pharma connected Thursday said its consolidated nett net declined 16.5 per cent to Rs 384 crore successful the 3rd 4th ended December 31, 2024.

The institution had reported a nett net of Rs 460 crore for the October-December play of past fiscal.

Revenue from operations roseate to Rs 3,230 crore from Rs 2,607 crore, Mankind Pharma said successful a statement.

"We achieved a steadfast gross maturation of 24 per cent YoY with beardown adjusted EBITDA borderline of 27.7 per cent successful Q3FY25, driven by continued retired show successful chronic, beardown betterment successful OTC and consolidation of BSV," Vice Chairman and MD Rajeev Juneja said.

Mankind Pharma has completed the transaction to get Bharat Serums and Vaccines (BSV), for a information of Rs 13,768 crore.

"The integration of BSV is connected track, with absorption connected mandate brands, improving productivity and adopting champion practices to guarantee semipermanent sustainable growth," Juneja stated.

The institution said its home concern grew 15.5 per cent year-on-year to Rs 2,773 crore successful the 3rd quarter.

Consumer healthcare concern gross stood astatine Rs 193 crore arsenic compared with Rs 149 crore successful December 4th past fiscal. Exports roseate to Rs 457 crore from Rs 207 crore.

Mankind shares connected Thursday ended higher 4.68 per cent astatine Rs 2,632.70 apiece connected the BSE.